Tennessee Generic Drug Settlement Funds: AG Urges Claims

• Tennessee Attorney General Jonathan Skrmetti is urging consumers to check their eligibility for compensation from generic drug settlements.
• The U.S. District Court for the District of Connecticut has granted preliminary approval for a distribution plan filed by Tennessee and 47 other states and territories.
• Settlements totaling approximately $96.5 million have been reached with generic drug manufacturers, including Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure, over allegations of price-fixing.
• Consumers who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible for restitution.
• Eligibility can be determined, and updates received, via a dedicated settlement website where claim forms will eventually be made available.

The preliminary approval of a comprehensive distribution plan marks a crucial step in returning millions of dollars from these settlements to individuals and entities harmed by alleged overcharges.

Tennessee Attorney General Jonathan Skrmetti has issued an urgent call for consumers to ascertain their eligibility for compensation stemming from a significant multistate settlement. These funds, known as the Tennessee generic drug settlement funds, originate from agreements reached with various generic drug manufacturers who faced accusations of unlawfully conspiring to artificially inflate drug prices.

This month, the U.S. District Court for the District of Connecticut granted preliminary approval for a comprehensive plan to distribute these settlement funds. This plan was collaboratively filed by Tennessee alongside a coalition comprising 47 other states and territories, marking a crucial step in addressing alleged widespread price manipulation within the pharmaceutical industry. The settlements specifically address claims that these companies engaged in illicit agreements with competitors to raise the prices of generic prescription drugs, impacting countless consumers nationwide. The multistate coalition previously announced settlements with companies including Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling approximately $96.5 million.

The core of this legal action lies in allegations of corporate collusion and antitrust violations pharmaceutical companies committed by manipulating the market for generic drugs. Attorney General Jonathan Skrmetti emphasized the illegality of corporate collusion to inflate drug prices, stating that such practices would not be tolerated within Tennessee. He further highlighted the collaborative, bipartisan efforts with attorneys general nationwide to ensure accountability for companies engaged in antitrust violations.

These settlements are the culmination of extensive investigations into multistate generic drug price-fixing schemes. The distribution plan aims to return millions of dollars from these collective settlement funds to consumers and other entities who may have been financially harmed by the alleged overcharges on generic drugs covered by these agreements. The preliminary approval by the District of Connecticut generic drug lawsuit court signifies a major advancement in providing restitution to those affected by these unlawful practices.

Individuals who purchased certain generic prescription drugs during a specific timeframe may be eligible for consumer compensation generic drugs. The eligibility window for these purchases spans from May 2009 through December 2019. It is important to note that qualification for compensation is contingent upon the specific generic drug purchased and other defined requirements.

Tennessee consumers who were affected by artificially inflated generic drug prices are now encouraged to determine their eligibility for restitution payments. A dedicated settlement website has been established where consumers can ascertain whether they meet the criteria for compensation. Additionally, individuals can register through this website to receive direct notifications regarding the claims process as it progresses. Claim forms will be made available via the settlement website and other designated channels once the claims process officially commences.

Lawyers should advise individual clients or small business clients in Tennessee who purchased certain generic prescription drugs between May 2009 and December 2019 to check their eligibility for compensation from this multistate settlement. Compliance officers in the pharmaceutical industry should note the continued enforcement against price-fixing and review their antitrust compliance programs.

Source: Reporting based on official statements from the Tennessee Attorney General's office.